| Name | Title | Contact Details |
|---|
Gliknik Inc., a biopharmaceuticals company, develops therapies for patients with cancer and immune disorders.
DxTech LLC is a Merrimack, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. ARCA`s lead development program is intended to be a direct implementation of those ideas. Gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (AF). ARCA has identified genetic variations in cardiac receptors that we believe may predict individual patient response to Gencaro™, giving Gencaro™ the potential to be the first genetically-targeted prevention treatment for AF. ARCA is also developing rNAPc2 as potential treatment for RNA-associated diseases, initially focused on COVID-19.
Our mission is to enable novel biological insights at the single-cell level for improved diagnosis and treatment of disease.
Diassess Inc. is revolutionizing the way infectious diseases are prevented, diagnosed, and monitored by developing the tools necessary to empower people to become knowledgeable about their health.